Inogen (NASDAQ:INGN) Stock Price Crosses Above 200-Day Moving Average – Here’s What Happened

Shares of Inogen, Inc. (NASDAQ:INGN) passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $10.23 and traded as high as $11.07. Inogen shares last traded at $10.64, with a volume of 340,965 shares traded.

Analyst Ratings Changes

INGN has been the topic of a number of recent research reports. StockNews.com upgraded shares of Inogen from a “hold” rating to a “buy” rating in a research note on Monday, February 10th. Needham & Company LLC reaffirmed a “hold” rating on shares of Inogen in a report on Thursday, January 30th.

Inogen Stock Down 0.2 %

The business’s 50 day moving average price is $10.07 and its 200-day moving average price is $10.24.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of INGN. Royce & Associates LP lifted its stake in shares of Inogen by 499.7% in the 4th quarter. Royce & Associates LP now owns 311,199 shares of the medical technology company’s stock worth $2,854,000 after acquiring an additional 259,308 shares during the period. Prudential Financial Inc. lifted its position in Inogen by 141.5% during the fourth quarter. Prudential Financial Inc. now owns 360,002 shares of the medical technology company’s stock valued at $3,301,000 after buying an additional 210,961 shares in the last quarter. Arrowstreet Capital Limited Partnership raised its stake in shares of Inogen by 154.8% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 263,561 shares of the medical technology company’s stock valued at $2,417,000 after purchasing an additional 160,106 shares during the period. Connor Clark & Lunn Investment Management Ltd. increased its stake in shares of Inogen by 312.5% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 174,625 shares of the medical technology company’s stock worth $1,694,000 after buying an additional 132,287 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its stake in Inogen by 25.4% during the fourth quarter. Dimensional Fund Advisors LP now owns 607,837 shares of the medical technology company’s stock valued at $5,574,000 after purchasing an additional 123,208 shares during the last quarter. Institutional investors and hedge funds own 89.94% of the company’s stock.

About Inogen

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.